More on NYSE
News
- Actinium Pharma (ATNM) Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML
- Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone
- Actinium Pharma (ATNM) Reports Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients
- Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Present
- Actinium Pharma (ATNM) Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy
- Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy
- Sony Group (SONY) tops FQ3 estimates, cuts PlayStation 5 sales outlook; shares rise
- Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
- HUGOTON ROYALTY TRUST DECLARES NO DECEMBER CASH DISTRIBUTION
- Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Expos
Entities mentioned with NYSE
- FDA | View Related Stories »
- Dividend | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- Cantor Fitzgerald | View Related Stories »
- H.C. Wainwright | View Related Stories »
- Jefferies & Co | View Related Stories »
- Mary Schapiro | View Related Stories »
- Show More...
